Ivermectin for Cancer: A Research Report
##
Introduction
Ivermectin, a well-known antiparasitic drug, has been the subject of research for its potential use in cancer treatment. This report synthesizes findings from various studies to explore the role of ivermectin in combating cancer, particularly its ability to reverse drug resistance, enhance the efficacy of chemotherapeutic drugs, and synergize with immune checkpoint inhibitors.
##
Ivermectin's Role in Reversing Drug Resistance
Ivermectin has been found to reverse drug resistance in cancer cells through the EGFR/ERK/Akt/NF-κB pathway. At low doses, which do not induce significant cytotoxicity, ivermectin can drastically reverse the resistance of tumor cells to chemotherapeutic drugs both in vitro and in vivo. This effect is particularly pronounced in drug-resistant cells, where ivermectin significantly enhances the anti-cancer efficacy of chemotherapeutic agents [[3][10]]. The mechanism involves ivermectin binding to the extracellular domain of EGFR, inhibiting its activation and downstream signaling cascades, which in turn reduces the expression of P-glycoprotein (P-gp), a molecule associated with drug resistance [[8][9]]. This suggests that ivermectin could be used in combination with chemotherapy to treat drug-resistant cancers [[4][11]].
##
Immunomodulatory Effects of Ivermectin in Cancer
Recent studies have highlighted ivermectin's immunomodulatory effects in cancer treatment. Ivermectin induces immunogenic cancer cell death (ICD) and promotes T cell infiltration into breast tumors, effectively converting 'cold' tumors into 'hot' ones [[12][16]]. This transformation is crucial as it enables the immune system to recognize and attack the tumor cells. Ivermectin also targets immunosuppressive cell populations, enhancing the ratio of effector T cells to regulatory T cells (Tregs). When combined with checkpoint inhibitors like anti-PD1 antibodies, ivermectin achieves a synergistic effect, limiting tumor growth and even leading to complete responses in some cases [[14][17][18][19]]. This combination therapy has shown promise in various settings, including neoadjuvant, adjuvant, and metastatic breast cancer [[20][27][28]].
##
Cost-Effectiveness and Accessibility
One of the notable advantages of ivermectin is its affordability. At approximately $30 per dose, ivermectin is accessible to a wide range of patients, including those in developing countries. This cost-effectiveness, combined with its potential efficacy, makes ivermectin an attractive option for cancer treatment in resource-limited settings.
##
Ivermectin's Efficacy in Various Cancer Types
Ivermectin has been shown to augment the anti-cancer activity of other drugs, such as pitavastatin in ovarian cancer cells. It inhibits the WNT-TCF pathway in human cancer and induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer [[30][31]]. Additionally, ivermectin has been identified as an inhibitor of cancer stem-like cells and can suppress ovarian cancer by regulating specific RNA axes [[32][33]]. It preferentially targets renal cancer by inducing mitochondrial dysfunction and oxidative damage. These findings suggest that ivermectin's anti-cancer properties may extend beyond breast cancer to other cancer types.
##
Current Status of Ivermectin as a Cancer Treatment
Despite the promising preclinical results, it is important to note that ivermectin is not currently recognized as a cure for cancer. There are no clinical trials that have conclusively demonstrated its efficacy in curing cancer in humans [[38][40][43]]. However, research continues to explore its potential when used in combination with other therapies [[41][44][47]]. The National Cancer Institute does not endorse ivermectin as a cancer cure, but the ongoing research suggests that its role in cancer treatment warrants further investigation.
##
Conclusion
Ivermectin shows potential as an adjunct therapy in cancer treatment, particularly due to its ability to reverse drug resistance and modulate the immune response. While it is not a standalone cure for cancer, its low cost and promising synergistic effects with other treatments make it a candidate for further clinical research. As studies continue, the hope is that ivermectin may become a valuable component in the multifaceted approach to cancer therapy.
